Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking.
The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.
By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.
The company was founded in 2016, through the merger of Roslin Cellab and Roslin Cell Sciences, and has facilities in both Edinburgh and Cambridge, UK.
Clinical Network Services (CNS) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Colibri Scientific provides fast and flexible clinical sample operational services to clinical investigators, biotechnology and pharmaceutical companies running small to medium scale multi-centre studies. Our team is made up of industry experts with many years’ experience in the field.
As our name suggests (Colibri – hummingbird), we are a small, agile and efficient company which offers a fully customisable service to meet the needs of our clients; something that is difficult to achieve from larger organisations. We aim to deliver the specific sample requirements of your trial, regardless how small, using a flexible approach together with scientific rigour and organisational expertise.
At Conversis we specialise in translating and localising marketing materials, educational content, websites and other digital platforms. Founded in 2003, we supply accurate and appropriately translated communications to clients in the corporate, pharmaceutical, marketing, technology and life sciences industries, among many others.
Built on a reputation for quality and the strong relationships we have developed with both our clients and suppliers, we support organisations in the Pharmaceutical, Oil & Gas, Marketing and Technology industries, among many other sectors.
Curileum Discovery Ltd is a new regenerative medicine company in London focused on identifying the underlying causes of serious gastrointestinal (GI) diseases, and repairing or replacing damaged cells in tissues. Effective tissue regeneration requires activation of endogenous healthy stem cells, rare cells in tissues that are the very source of lifelong tissue renewal.
We are applying three decades of stem cell drug discovery and development experience to unlock a whole new range of therapeutic targets to kill defective stem cells and to activate healthy stem cells to restore health to the intestine.
The company, is able to offer expertise in the manufacture, analytical testing and packing of solid dose medicinal products across a range of therapeutic areas to a wide range of clients. In addition, the organisation is able to offer to the marketplace, expertise and assistance in new and existing product development, regulatory support and also technical support for ongoing client projects.